Metformin Sustained Release 500 Mg (Generic)

Product Overview

Metformin Sustained Release 500 Mg (Generic) is a prescription oral antihyperglycemic agent formulated for the management of type 2 diabetes mellitus. Produced by USV Pvt Ltd, this tablet belongs to the biguanide class and delivers the active ingredient in a controlled‑release matrix that extends therapeutic activity over approximately 24 hours, providing a steady plasma concentration that supports consistent glycemic control throughout the day. The product is packaged in sealed foil strips containing 20 tablets, and manufacturers offer bulk pack options of 100, 200, and 300 tablets to suit diverse patient needs and treatment plans. Each batch undergoes rigorous quality assurance testing in compliance with current Good Manufacturing Practices (cGMP) and meets the specifications set by the United States Pharmacopeia (USP). The formulation is bioequivalent to reference branded products, meaning it delivers the same therapeutic effect when administered at the same dose, and it is approved by the US Food and Drug Administration (FDA) for safety, efficacy, and quality.

What is Metformin Sustained Release 500 Mg (Generic)

Metformin is the most widely prescribed oral medication for type 2 diabetes worldwide. The sustained‑release (SR) formulation releases the drug slowly, allowing a lower peak concentration and a more stable plasma level compared with immediate‑release tablets. Each 500 mg tablet provides a dose that is equivalent to the daily therapeutic dose of immediate‑release metformin when taken once daily, but with the convenience of a single daily administration. The generic version contains the same active ingredient—metformin hydrochloride—at the same strength, and is bioequivalent to the brand‑name product, ensuring identical clinical outcomes when used as directed. Because the SR form maintains consistent drug levels, it often improves patient adherence and may reduce the incidence of gastrointestinal side effects that are sometimes observed with immediate‑release formulations. For a detailed scientific review, see the NIH Diabetes page NIH Diabetes Resources.

Uses and Benefits

The primary indication for Metformin Sustained Release 500 Mg is the improvement of glycemic control in adults with type 2 diabetes mellitus, particularly when lifestyle modification alone is insufficient. Clinical studies demonstrate that SR therapy achieves a modest reduction in hemoglobin A1c (HbA1c) of approximately 0.5 to 1.0 percent, while also supporting modest weight neutrality and a low risk of hypoglycemia when used without sulfonylureas or insulin. Additional cardiovascular benefits have been observed in patients with diabetes and established atherosclerotic disease, making this medication a cornerstone of comprehensive diabetes management. Its once‑daily dosing schedule improves adherence, and the extended‑release profile minimizes gastrointestinal discomfort that is sometimes associated with immediate‑release formulations. Moreover, real‑world evidence suggests that sustained‑release therapy may be associated with lower rates of treatment discontinuation, contributing to long‑term disease control. For more information on cardiovascular outcomes, refer to the FDA label FDA prescribing information.

How It Works

Metformin exerts its glucose‑lowering effect through multiple mechanisms that act primarily in the liver and peripheral tissues. It suppresses hepatic gluconeogenesis, thereby decreasing the liver’s production of glucose. Simultaneously, it enhances peripheral insulin sensitivity, facilitating greater glucose uptake by muscle and adipose tissue. The sustained‑release matrix ensures a gradual increase in plasma concentrations, which maintains therapeutic activity throughout the dosing interval and reduces the peak‑related side‑effect profile. By improving insulin action without stimulating insulin secretion, Metformin does not cause hypoglycemia when used as monotherapy, and it is also associated with favorable metabolic outcomes such as decreased triglyceride levels, reduced low‑density lipoprotein (LDL) cholesterol, and modest weight loss in some patients. For an in‑depth mechanistic overview, see the MedlinePlus page Metformin Information.

Dosage Guidelines

Treatment with Metformin Sustained Release 500 Mg typically begins with one tablet taken once daily with the evening meal to reduce the likelihood of gastrointestinal upset. The dose may be titrated upward, based on glycemic response and tolerability, to a maximum of 1000 mg twice daily (total 2000 mg per day) under medical supervision. Adjustments are recommended for patients with renal impairment, as metformin is cleared renally; a reduced dose or alternative therapy may be required when estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73 m². Physicians may also consider dose modifications in elderly patients, during periods of acute illness, or before surgical procedures that involve contrast administration. Regular assessment of renal function is recommended, with dosing adjustments based on eGFR to minimize the risk of accumulation. Patients should always follow the dosing instructions provided by their healthcare provider and should not alter the regimen without professional guidance.

Side Effects

Like all medications, Metformin Sustained Release 500 Mg can be associated with adverse effects. The most common are gastrointestinal in nature, including nausea, abdominal discomfort, diarrhea, and a transient metallic taste. These symptoms are usually mild and tend to improve with continued use or by taking the tablet with food. Rare but serious adverse events include lactic acidosis, a condition characterized by the accumulation of lactate in the bloodstream that can be life‑threatening if not recognized early. Signs of lactic acidosis may include rapid breathing, muscle pain, extreme weakness, dizziness, and abdominal discomfort. Patients should seek immediate medical attention if they experience any of these symptoms. Additional less‑frequent side effects may involve vitamin B12 deficiency with long‑term use, which can manifest as peripheral neuropathy or anemia. Periodic evaluation of vitamin B12 levels is advisable for patients on long‑term therapy, as deficiency can develop over time. Consumer information is available at MedlinePlus.

Warnings and Precautions

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and any condition that predisposes to hypoxemia or hepatic dysfunction. It should be discontinued prior to undergoing radiographic studies that involve iodinated contrast agents, and patients must be monitored for renal function while on therapy. Caution is advised in elderly individuals, during pregnancy, and in lactating women, as the safety profile may differ from that observed in non‑pregnant adults. In pregnant women, metformin is generally considered safe for management of gestational diabetes when insulin is not indicated, but dosage must be carefully titrated under obstetric supervision. Concomitant use of certain investigational drugs that affect glucose metabolism may require additional safety monitoring. Concomitant use of certain medications—such as certain contrast agents, certain anesthetics, or drugs that affect renal perfusion—may increase the risk of lactic acidosis. Patients should inform their healthcare provider of all prescription and non‑prescription medications, as well as any herbal supplements, to ensure safe co‑administration.

Frequently Asked Questions

Q: How should I take Metformin Sustained Release 500 Mg?
A: Take one tablet daily with the evening meal, preferably with food, and swallow it whole; do not crush or split the tablet.

Q: Can Metformin cause low blood sugar?
A: When used alone, Metformin does not typically cause hypoglycemia, but the risk increases if combined with other glucose‑lowering agents; always monitor blood glucose as advised by your clinician.

Q: What should I do if I miss a dose?
A: If you remember the missed dose within a few hours, take it with food; if it is near the time of your next scheduled dose, skip the missed dose and resume your regular schedule—do not double up.

Q: Are there any foods or drinks to avoid?
A: Avoid excessive alcohol intake and be cautious with high‑carbohydrate meals that may affect glucose control; discuss any dietary changes with your healthcare provider.

Q: How long does it take to see improvements in blood sugar levels?
A: Most patients observe a modest reduction in fasting glucose within 1–2 weeks, with maximal HbA1c lowering effect typically achieved after 4–6 weeks of consistent therapy.

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)